Literature DB >> 407651

Purine nucleoside phosphorylase deficiency: altered kinetic properties of a mutant enzyme.

I H Fox, C M Andres, E W Gelfand, D Biggar.   

Abstract

Erythrocyte purine nucleoside phosphorylase from two brothers had 0.5% of normal activity. It differed from the normal enzyme by a tenfold increase in the Michaelis constant for inosine, an inability of inosine to protect against thermal lability, and a more positive net charge. The altered kinetic properties may account for the milder disease in the patients compared to the previously described cases. The data provide evidence for a structural gene mutation and genetic heterogeneity in the new disease of purine nucleoside phosphorylase deficiency and T cell dysfunction.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 407651     DOI: 10.1126/science.407651

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  9 in total

Review 1.  Combined immunodeficiency and inborn errors of purine metabolism.

Authors:  H J Meuwissen; B Pollara
Journal:  Blut       Date:  1978-10-13

2.  Normal B-lymphocyte function in patients with Lesch-Nyhan syndrome and HGPRT deficiency.

Authors:  E W Gelfand; I H Fox; M Stuckey; H M Dosch
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

3.  Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients.

Authors:  M L Markert; M S Hershfield; R I Schiff; R H Buckley
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

Review 4.  Nucleotide-metabolizing enzymes and lymphocyte differentiation.

Authors:  R W Barton; I Goldschneider
Journal:  Mol Cell Biochem       Date:  1979-12-14       Impact factor: 3.396

5.  Partial purine nucleoside phosphorylase deficiency. Studies of lymphocyte function.

Authors:  E W Gelfand; H M Dosch; W D Biggar; I H Fox
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

6.  Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency.

Authors:  M R Aust; L G Andrews; M J Barrett; C J Norby-Slycord; M L Markert
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

7.  Altered purine and pyrimidine metabolism in erythrocytes with purine nucleoside phosphorylase deficiency.

Authors:  I H Fox; J Kaminska; N L Edwards; E Gelfand; K C Rich; W N Arnold
Journal:  Biochem Genet       Date:  1980-04       Impact factor: 1.890

8.  Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy.

Authors:  S L Sacks; T C Merigan; J Kaminska; I H Fox
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

9.  Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combine immunodeficiency.

Authors:  F X Arredondo-Vega; J Kurtzberg; S Chaffee; I Santisteban; E Reisner; M S Povey; M S Hershfield
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.